1
|
Feng J, Liu Y, Tian X, Shen C, Feng Z, Zhang J, Yao X, Pu M, Miao X, Ma L, Liu S. Discovery of novel peptide-dehydroepiandrosterone hybrids inducing endoplasmic reticulum stress with effective in vitro and in vivo anti-melanoma activities. Eur J Med Chem 2024; 269:116296. [PMID: 38467086 DOI: 10.1016/j.ejmech.2024.116296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2024] [Revised: 02/23/2024] [Accepted: 02/29/2024] [Indexed: 03/13/2024]
Abstract
Steroid hybrids have emerged as a type of advantageous compound as they could offer improved pharmacological and pharmaceutical properties. Here, we report a series of novel peptide-dehydroepiandrosterone hybrids, which would effectively induce endoplasmic reticulum stress (ERS) and lead to apoptosis with outstanding in vitro and in vivo anti-melanoma effects. The lead compound IId among various steroids conjugated with peptides and pyridines showed effective in vivo activity in B16 xenograft mice: in medium- and high-dose treatment groups (60 and 80 mg/kg), compound IId would significantly inhibit the growth of tumours by 98%-99% compared to the control group, with the highest survival rate as well. Further mechanism studies showed that compound IId would damage the endoplasmic reticulum and upregulate the ERS markers C/EBP homologous protein (CHOP) and glucose-regulated protein 78 (GRP78), which could further regulate caspase and Bcl-2 family proteins and lead to cell apoptosis. The compound IId was also proven to be effective in inhibiting B16 cell migration and invasion.
Collapse
Affiliation(s)
- Juan Feng
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China
| | - Yidong Liu
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China.
| | - Xia Tian
- School of Science, Hebei University of Science and Technology, Shijiazhuang, 050022, Hebei, China
| | - Chen Shen
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China
| | - Zhiqiang Feng
- Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China
| | - Jingxu Zhang
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China
| | - Xiangli Yao
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China
| | - Meilin Pu
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China
| | - Xuguang Miao
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China
| | - Lan Ma
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China
| | - Shouxin Liu
- State Key Laboratory Breeding Base-Hebei Key Laboratory of Molecular Chemistry for Drug, Hebei Collaborative Innovation Centre of New Drug Creation, College of Chemistry and Pharmaceutical Engineering, Hebei University of Science and Technology, No. 26 Yuxiang Street, Shijiazhuang, 050022, Hebei, China.
| |
Collapse
|
2
|
Oka Y, Abe-Sato K, Tabuse H, Yasukawa Y, Yahara T, Nishimoto T, Kamitani M, Fukunaga T, Ochiai N, Kumasaka-Abe T, Hitaka K, Gunji E, Ohara H, Takeda T, Kojima N, Asami T. Discovery of TP0628103: A Highly Potent and Selective MMP-7 Inhibitor with Reduced OATP-Mediated Clearance Designed by Shifting Isoelectric Points. J Med Chem 2024; 67:1406-1420. [PMID: 38214909 DOI: 10.1021/acs.jmedchem.3c01967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2024]
Abstract
Matrix metalloproteinase-7 (MMP-7) has been shown to play an important role in pathophysiological processes such as cancer and fibrosis. We previously discovered selective MMP-7 inhibitors by molecular hybridization and structure-based drug design. However, the systemic clearance (CLtot) of the biologically active lead compound was very high. Because our studies revealed that hepatic uptake by organic anion transporting polypeptide (OATP) was responsible for the high CLtot, we found a novel approach to reducing their uptake based on isoelectric point (IP) values as an indicator for substrate recognition by OATP1B1/1B3. Our "IP shift strategy" to adjust the IP values culminated in the discovery of TP0628103 (18), which is characterized by reduced in vitro OATP-mediated hepatic uptake and in vivo CLtot. Our in vitro-in vivo extrapolation of OATP-mediated clearance and the "IP shift strategy" provide crucial insights for a new medicinal chemistry approach to reducing the systemic clearance of OATP1B1/1B3 substrates.
Collapse
Affiliation(s)
- Yusuke Oka
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Kumi Abe-Sato
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Hideaki Tabuse
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Yoshifumi Yasukawa
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tohru Yahara
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tomohiro Nishimoto
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Masafumi Kamitani
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Takuya Fukunaga
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Nagahiro Ochiai
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Tomoko Kumasaka-Abe
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Kosuke Hitaka
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Emi Gunji
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Hiroki Ohara
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Takuya Takeda
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Naoki Kojima
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| | - Taiji Asami
- Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama 331-9530, Japan
| |
Collapse
|
3
|
Abe-Sato K, Tabuse H, Kanazawa H, Kamitani M, Endo M, Tokura S, Wakabayashi S, Yahara T, Takeda T, Hitaka K, Gunji E, Kojima N, Oka Y. Structure-Based Optimization and Biological Evaluation of Potent and Selective MMP-7 Inhibitors for Kidney Fibrosis. J Med Chem 2023; 66:14653-14668. [PMID: 37861435 DOI: 10.1021/acs.jmedchem.3c01166] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2023]
Abstract
Matrix metalloproteinase-7 (MMP-7) has been shown to play important roles in pathophysiological processes involved in the development/progression of diseases such as cancer and fibrosis. We discovered selective MMP-7 inhibitors composed of arylsulfonamide, carboxylate, and short peptides by a molecular hybridization approach. These compounds interacted with MMP-7 via multiple hydrogen bonds in the cocrystal structures. To obtain compounds for in vivo evaluation, we attempted structural optimization, particularly targeting Tyr167 at the S3 subsite through structure-based drug design, and identified compound 15 as showing improved MMP-7 potency and MMP subtype selectivity. A novel π-π stacking interaction with Tyr167 was achieved when 4-pyridylalanine was introduced as the P3 residue. Compound 15 suppressed the progression of kidney fibrosis in a dose-dependent manner in a mouse model of unilateral ureteral obstruction. Thus, we demonstrated, for the first time, that potent and selective MMP-7 inhibitors could prevent the progression of kidney fibrosis.
Collapse
Affiliation(s)
- Kumi Abe-Sato
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Hideaki Tabuse
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Harumi Kanazawa
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Masafumi Kamitani
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Mayumi Endo
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Seiken Tokura
- Discovery Technologies Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Satoshi Wakabayashi
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Tohru Yahara
- Drug Metabolism and Pharmacokinetics Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Takuya Takeda
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Kosuke Hitaka
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Emi Gunji
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Naoki Kojima
- Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| | - Yusuke Oka
- Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-Cho, Kita-Ku, Saitama, Saitama 331-9530, Japan
| |
Collapse
|